jun 4, 2019: 2 p.m. - 3 p.m.
107AB, Level 100
Many pharma companies partner with diagnostic companies to develop, manufacture and commercialize the diagnostics they need for approval and successful commercialization of their own new therapies. Over the last several years, these partnerships have spiked thanks to FDA and other regulatory agencies increasingly approving drugs with companion diagnostics. This panel will explore key learnings from the current model of pharma-diagnostic partnerships, as well as the new and more creative ways of partnering on the horizon.